Laurel Wealth Advisors (California)’s iShares Biotechnology ETF IBB Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$412K	Buy	3,138 +356	+13%	+$46K	0.04%	408
2022 Q3	$325K	Sell	2,782 -683	-20%	-$84.8K	0.03%	463
2022 Q2	$408K	Buy	3,465 +446	+15%	+$52.9K	0.04%	409
2022 Q1	$393K	Buy	3,019 +557	+23%	+$72.6K	0.03%	498
2021 Q4	$376K	Buy	2,462 +799	+48%	+$124K	0.03%	553
2021 Q3	$269K	Sell	1,663 -635	-28%	-$107K	0.05%	366
2021 Q2	$376K	Sell	2,298 -22	-0.9%	-$3.39K	0.05%	345
2021 Q1	$349K	Sell	2,320 -214	-8%	-$34K	0.05%	324
2020 Q4	$384K	Sell	2,534 -122	-5%	-$17.4K	0.06%	296
2020 Q3	$360K	Buy	2,656 +14	+0.5%	+$1.9K	0.06%	275
2020 Q2	$361K	Buy	2,642 +387	+17%	+$49.3K	0.07%	266
2020 Q1	$243K	Buy	2,255 +269	+14%	+$31K	0.06%	319
2019 Q4	$240K	Buy	+1,986	New	+$222K	0.04%	404
2016 Q2	–	Sell	-300	Closed	-$26K	–	298
2016 Q1	$26K	Buy	+300	New	+$26.8K	0.01%	277

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CANY

Caxton Associates (New York) New York $3.18B AUM 54.49% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Laurel Wealth Advisors (California)'s IBB Position: Q4 2022 in Review

Laurel Wealth Advisors (California) increased its iShares Biotechnology ETF (IBB) stake by 13% in Q4 2022, buying an estimated $46K and bringing the position to 3,138 shares worth $412K. The position accounts for 0.04% of the portfolio, ranked #408.

Laurel Wealth Advisors (California) first reported a position in IBB in Q1 2016 and has held it in 14 quarters since. 902 funds tracked by Wall St. Rank hold IBB as of Q4 2022.

Laurel Wealth Advisors (California) held 3,138 shares of iShares Biotechnology ETF worth $412K as of Q4 2022.
Laurel Wealth Advisors (California) bought 356 iShares Biotechnology ETF shares in Q4 2022, an estimated $46K.
iShares Biotechnology ETF made up 0.04% of Laurel Wealth Advisors (California)'s portfolio in Q4 2022, its #408 holding.
Laurel Wealth Advisors (California) first reported a position in iShares Biotechnology ETF in Q1 2016 and has held it in 14 quarters since.
902 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2022, filed 14 Feb 2023.